Hepatitis A Vaccines Shield Nearly 96% of Recipients, Largest Evidence Synthesis to Date Finds

A sweeping new systematic review and meta-analysis published in eClinicalMedicine has delivered the most comprehensive quantitative assessment yet of hepatitis A vaccination, concluding that the vaccines prevent roughly 96% of infections when given before exposure and about 97% when administered after a known exposure. The analysis, conducted by researchers in the Czech Republic and drawing on more than four decades of clinical and programmatic data, also found that vaccination programmes have slashed hepatitis A incidence in children by 80% to 100% at the population level — a finding with major implications for countries navigating the shifting epidemiology of this liver disease.

Hepatitis A virus remains a leading cause of acute viral hepatitis worldwide. Although infection in young children is frequently asymptomatic, older children, adolescents, and adults are far more likely to develop clinically apparent illness, and in rare cases the disease progresses to acute liver failure. Paradoxically, as sanitation, hygiene, and access to clean water improve in many regions, hepatitis A transmission falls — but the result is a growing pool of susceptible older individuals in whom infection is more often symptomatic and severe. This epidemiological transition has intensified interest in vaccination as both a routine preventive tool and an outbreak-control measure.

The research, registered as HAVETO (Hepatitis A Vaccine Effectiveness: Trials and Observational Studies), searched MEDLINE, EMBASE, Biological Abstracts, the Cochrane Central Register of Controlled Trials, PubMed, and Scopus for studies published between January 1985 and April 2026, without language restrictions. The team applied PRISMA and MOOSE reporting guidelines and assessed the certainty of evidence using the GRADE framework, with risk of bias evaluated by the RoB 2 tool for randomised trials and ROBINS-I for observational studies. Crucially, eligible studies were required to confirm hepatitis A outcomes using laboratory verification by IgM anti-HAV antibodies, filtering out studies that relied on clinical symptoms alone.

The final meta-analysis included 21 publications. Pre-exposure vaccine effectiveness drew on 15 estimates from six randomised controlled trials and eight cohort studies, while post-exposure effectiveness was evaluated using eight estimates from one randomised trial and seven cohort studies. The evidence base was dominated by studies in children and adolescents, with only two adult cohorts — one in people living with HIV in Taiwan and one in South Korean military personnel.

The headline numbers were striking. Pooled effectiveness of pre-exposure vaccination reached 95.8% (95% confidence interval 93.1–97.4), backed by raw event counts showing just 20 hepatitis A infections among 925,238 vaccinated individuals compared with 1,029 infections among 1,708,753 unvaccinated people. The estimate was remarkably stable across vaccine platforms: inactivated vaccines showed pooled effectiveness of 97.2% in children, and live attenuated vaccines — evaluated exclusively in Chinese children — reached 96.0%. Both were supported by moderate-certainty evidence. When restricted to randomised trials in children, the pooled effectiveness climbed to 97.5% with high-certainty evidence, the strongest rating in the entire analysis.

Post-exposure vaccination — typically administered within 14 days of a known exposure, replacing or complementing the shorter-acting immune globulin that historically served this role — yielded a pooled effectiveness of 96.9%, with similar values in close-contact settings (95.3%) and outbreak-area populations (98.4%). Here, however, the researchers urge caution: the certainty of evidence was rated very low, owing to serious limitations, inconsistency, and indirectness across the largely observational studies. A wide prediction interval, with a lower bound below zero, underscored the uncertainty even as the point estimate remained high.

Perhaps the most policy-relevant component of the study was its ecological analysis. Drawing on 19 before-and-after studies of national and regional childhood vaccination programmes conducted between 1997 and 2024, the team used a Bayesian regression model to estimate population-level vaccine impact. The reference scenario — vaccinated children under 5 years old, coverage up to 60%, and pre-vaccination incidence below 10 cases per 100,000 person-years — produced an impact estimate of 83.9%. Notably, impact rose by about 8 percentage points in settings where pre-vaccination incidence exceeded 100 cases per 100,000 person-years, suggesting that baseline disease burden is a more important determinant of programme success than coverage levels or the age of the target population.

That last finding carries real weight for immunisation policy. Vaccination coverage across the included programmes ranged from 40% to 95%, yet this variability did not clearly explain differences in impact. The authors suggest that vaccinating young children reduces transmission more broadly, extending protection to older, unvaccinated age groups — a phenomenon consistent with previous reports of declining hepatitis A incidence among adults after childhood programmes were introduced in countries such as Israel and Argentina. In practical terms, even partial childhood coverage can generate substantial community-wide benefit.

The synthesis also fills a genuine gap in the literature. Previous reviews of hepatitis A vaccination have focused largely on immunogenicity, antibody persistence, or individual programme experiences, but no prior meta-analysis had jointly quantified pre-exposure and post-exposure effectiveness and linked those estimates to population-level impact. By combining clinical effectiveness data with ecological evidence, the HAVETO analysis offers policymakers a more complete picture of how individual protection translates into public-health benefit — and the picture is overwhelmingly positive.

Limitations remain, however. The evidence was methodologically heterogeneous, particularly regarding the definition of risk windows and follow-up durations. The pooled estimates refer to vaccination with at least one dose, so the additional benefit of two-dose schedules could not be reliably disentangled — a question sharpened by one South Korean study of single-dose vaccination in military recruits that reported lower effectiveness (76%) than most other studies. Adult data are sparse, long-term persistence of protection could not be robustly assessed, and one small molecular study has raised the theoretical possibility that vaccination during active infection could exert selective pressure on viral antigenic variants.

Nevertheless, the authors conclude that hepatitis A vaccination provides very high protection at the individual level and substantial benefit at the population level, strengthening the case for routine childhood immunisation and for its use in outbreak response, particularly in settings with higher baseline incidence. The findings arrive as a position paper from the European Society of Clinical Microbiology and Infectious Diseases has advocated universal hepatitis A vaccination as a pathway toward global immunity and eventual eradication. With effectiveness approaching 96% and population impact often approaching or exceeding 90% in high-incidence settings, the evidence now firmly supports that ambition — provided researchers can shore up the still-thin evidence base for post-exposure use and adult vaccination.